SCHEMBL23924567

SCHEMBL23924567

CC(C)CCCC(C)[C]=O

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
BLM P54132 1/20 0.38
KDM4C Q9H3R0 2/20 0.31
KDM4A O75164 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870968 0.93 LMNA (0.59) LMNABLM
SCHEMBL6141164 0.82
SCHEMBL8944983 0.78 LMNA (0.46) LMNABLM
SCHEMBL270381 0.78
SCHEMBL9368619 0.78
SCHEMBL10645891 0.76
SCHEMBL277789 0.76
SCHEMBL933698 0.76
SCHEMBL9943608 0.76
SCHEMBL42290 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11844775-B2 Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2023-12-19 US claimed
US-20210353581-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-11-18 US claimed
US-20210322357-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-10-21 US claimed
WO-2024030367-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-02-08 WO disclosed
US-11844775-B2 Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2023-12-19 US disclosed
US-20210353581-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-11-18 US disclosed
US-20210322357-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353581-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids ELOVL6, ELOVL3, CPT1B LMNA 2477/4885BLM 3348/4885KDM4C 4592/4885
US-11844775-B2 Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids ELOVL6, ELOVL3, CPT1B LMNA 2551/4885BLM 3418/4885KDM4C 4580/4885
US-20210322357-A1 Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids ELOVL6, ELOVL3, CPT1B LMNA 2551/4885BLM 3418/4885KDM4C 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.